Drugs / Velneperit
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01126970 | Apr 2010 → Jan 2011 | obesity disorder | Shionogi | Completed | No outcome recorded |
| Phase 2 | NCT00788528 | Aug 2008 → Feb 2010 | obesity disorder | Shionogi | Completed | No outcome recorded |
| Phase 2 | NCT00747929 | Jun 2007 → Nov 2008 | obesity disorder | Shionogi | Completed | No outcome recorded |
| Phase 2 | NCT00748605 | Jun 2007 → Nov 2008 | obesity disorder | Shionogi | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | velneperit | “S-2367 (velneperit)” NCT00788528 ↗ |
| Known as | S-2367 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00748605 ↗ |
| Action | Inhibit | “Neuropeptide Y receptor type 5 antagonist” CHEMBL2016681 ↗ |
| Modality | Small molecule | — CHEMBL2016681 ↗ |
| Route | Oral | “administered orally once-a-day” NCT00747929 ↗ |
| Target | NPY5R | “Neuropeptide Y receptor type 5 antagonist” CHEMBL2016681 ↗ |